Evaluation of the efficacy of Chinese herbal medicine Rhizoma arisaemetis preparata in the treatment of high-risk HPV persistent infection in female by transvaginal administratio
- Conditions
- HPV infection in female genital tract
- Registration Number
- ITMCTR2000003370
- Lead Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
The patient whose high-risk HPV screening result was positive,while after treatment, the review result was still the same type of high-risk HPV.
1. Patients who was pregnancy, delivery or abortion within 4 weeks, gestational trophoblastic disease;
2. Patients who used other vaginal preparations or lotions within 6 weeks before entering the clinical trial;
3. Patients who had taken antiviral drugs orally within 6 weeks before entering the clinical trial;
4. At present, there are other types of malignant tumor, or other malignant tumor recurrence can not be excluded;
5. Acute phase of other diseases: disturbance of consciousness, body temperature greater than 38 degrees C vital signs instability or acute abdomen, etc.;
6. Significant organ dysfunction: liver enzyme > 5 times normal upper limit, creatinine > 3 times normal upper limit, blood amylase > 2 times normal upper limit, cardiac function 3-4 grade, etc.;
7. Mental illness patients receiving medication.
8. Eliminate trichomonas, mold, Neisseria gonorrhoeae, chlamydia, mycoplasma any kind of infection.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method high-risk HPV;TCT (LCT);Vaginal secretions routine;
- Secondary Outcome Measures
Name Time Method